Gao Fei-Qiong, Zhu Jia-Qi, Feng Xu-Dong
Department of Endocrinology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310003, Zhejiang Province, China.
Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China.
World J Stem Cells. 2024 Sep 26;16(9):846-853. doi: 10.4252/wjsc.v16.i9.846.
The incidence of non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD) is increasing year by year due to changes in the contemporary environment and dietary structure, and is an important public health problem worldwide. There is an urgent need to continuously improve the understanding of their disease mechanisms and develop novel therapeutic strategies. Mesenchymal stem cells (MSCs) have shown promise as a potential therapeutic strategy in therapeutic studies of NAFLD and ALD. NAFLD and ALD have different triggers and their specific mechanisms of disease progression are different, but both involve disease processes such as hepatocellular steatosis and potential fibrosis, cirrhosis, and even hepatocellular carcinoma. MSCs have metabolic regulatory, anti-apoptotic, antioxidant, and immunomodulatory effects that together promote liver injury repair and functional recovery, and have demonstrated positive results in preclinical studies. This editorial is a continuum of Jiang 's review focusing on the advantages and limitations of MSCs and their derivatives as therapeutics for NAFLD and ALD. They detail how MSCs attenuate the progression of NAFLD by modulating molecular pathways involved in glucolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. Based on recent advances, we discuss MSCs and their derivatives as therapeutic strategies for NAFLD and ALD, providing useful information for their clinical application.
由于当代环境和饮食结构的变化，非酒精性脂肪性肝病（NAFLD）和酒精性肝病（ALD）的发病率逐年上升，是全球重要的公共卫生问题。迫切需要不断加深对其发病机制的认识，并开发新的治疗策略。间充质干细胞（MSCs）在NAFLD和ALD的治疗研究中已显示出作为一种潜在治疗策略的前景。NAFLD和ALD有不同的触发因素，其疾病进展的具体机制也不同，但两者都涉及肝细胞脂肪变性以及潜在的纤维化、肝硬化甚至肝细胞癌等疾病过程。MSCs具有代谢调节、抗凋亡、抗氧化和免疫调节作用，共同促进肝损伤修复和功能恢复，并在临床前研究中取得了积极成果。这篇社论是蒋氏综述的延续，重点关注MSCs及其衍生物作为NAFLD和ALD治疗方法的优缺点。他们详细阐述了MSCs如何通过调节参与糖脂代谢、炎症、氧化应激、内质网应激和纤维化的分子途径来减轻NAFLD的进展。基于最近的进展，我们讨论了MSCs及其衍生物作为NAFLD和ALD的治疗策略，为其临床应用提供有用信息。
